Summary of CEDAC Discussion
Meeting Date

GENERIC DRUG NAME
(Brand Name – Manufacturer)

Note: The Summary of the CEDAC Discussion is approximately two pages long; thus, the description in each section is brief.

CEDAC Members Participating (Via Videoconference/In Person):
List of members present.

Regrets:
List of members who could not attend.

Conflict of Interest:
CEDAC members’ conflicts of interest, related to this submission, are recorded and the decisions as to whether or not members are excused from voting are recorded.

Description of Generic Drug Name (Brand Name – Manufacturer):
A brief description (four to five sentences) of the indication and action of the drug is provided.

Discussion of Clinical and Pharmacoeconomic Reviews:
CEDAC considered a systematic review of published and unpublished clinical studies prepared by CDR and a CDR review of a pharmacoeconomic evaluation supplied by the manufacturer. An overview of these reviews is available at (www.cadth.ca).

The following information was presented by a CEDAC member, based on the CDR clinical and pharmacoeconomic reviews:

1. Therapeutic rationale/need
A brief description of the therapeutic need for the drug is provided. This may include the prevalence of the indicated condition and/or the limitations of existing therapy.

2. Clinical trials
A description of the number and type of studies, their overall quality and size, and patient populations in the included studies is presented.

3. Comparators/Other available treatment options
The comparators, drug or non-drug, that were studied in the included trials are listed; as well, those that are relevant but were not included in the studies are presented.

Common Drug Review
CEDAC Meeting – Month Day, Year
4. Outcomes
The outcomes that are considered in the review are listed, together with a comment on their clinical importance (relevance and validity). Also, outcomes that are considered important but are not studied are noted.

5. Effectiveness
Conclusions about the effectiveness of the drug compared to the selected comparator drug or non-drug therapies are provided. Areas where data are lacking are identified.

6. Safety/tolerability (harms)
Findings about the safety/tolerability (or harms) compared to other therapies are described. Areas where data are lacking are identified.

7. Cost and pharmacoeconomic evaluation
Comparative cost and cost-effectiveness are provided.

Discussion Points:
In this section, discussion points that were raised and considered by CEDAC, in addition to the information above, are briefly described.

CEDAC Recommendation and Reasons for Recommendation:
Members voted on the recommendation regarding the listing of the drug under review. The Recommendation and Reasons for Recommendation will be forwarded to the manufacturer and participating drug plans in accordance with the Procedure for Common Drug Review.